Role of Immunohistochemistry in The Subtyping of Non Small Cell Lung Carcinoma on True Cut Lung Biopsies
DOI:
https://doi.org/10.21276/apalm.1839Keywords:
Adenocarcinoma, squamous cell carcinoma, CK7, CK5, CK6, P63, Napsin-A, TTF1Abstract
BACKGROUND: Worldwide, lung carcinoma is the most common cancer in terms of number of cases and deaths. Lung carcinomas are broadly divided into small cell carcinoma and non-small cell lung carcinoma(NSCLC). In recent years availability of targeted therapies necessitated subtyping the NSCLC to improve the survival and quality of life. NSCLC can be subtyped by routine Haematoxylin and Eosin (H&E) stained section slides alone, poorly differentiated tumors are difficult to segregate morphologically, especially in true-cut biopsies, necessitating ancillary techniques like immunohistochemistry (IHC). Hence this study was taken up to examine accuracy of diagnosis of Non-Small Cell Lung Carcinoma (NSCLC) on biopsy samples initially made based on morphology and then with IHC using relevant markers like CK5, CK6, CK7, Napsin-A, TTF-1, P63, Synaptophysin and Chromogranin-A.
METHODS: A prospective study of two years and six months duration during which
111 cases of NSCLC on true-cut biopsies were first reported on Haematoxylin and
Eosin sections and later subjected for IHC.
RESULTS: Out of 111 cases, after IHC, 80 were diagnosed as adenocarcinoma and
31 as squamous cell carcinoma NSCLC were common in the 6th decade. In
adenocarcinoma positivity for CK7, TTF1 and Napsin-A was 95%, 75%and 78.75%
respectively. In squamous cell carcinoma positivity for CK5, CK6 and P63 was 84%,
81% and 90% respectively.
CONCLUSION: CK5, CK6 and P63 can be used for confirming squamous cell
carcinoma and CK7, TTF-1 and Napsin-A for adenocarcinoma. We recommend a
IHC panel consisting of P63, TTF1 and Napsin-A in NSCLC-unclassifiable and
poorly differentiated carcinoma on H&E.
References
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mahters C, et al. GLOBOCAN 2012 v1.0,Cancr Incidence and Mortality Worldwide: IARC Cancer Base No. 11.Lyon, France; International Agency for Reasearch on cancer; 2013.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of world burden of cancer in 2008. Int. J. Cancer 2010; 127: 2893-2917.
Husian Aliya N. The Lung: Tumours. In: Kumar, Abbas,Aster (Eds). Robbins and Cotran Pathologic basis of disease: 9thed.Elsevier ;2015.
Grilley-Olson JE, Hayes DN, Moore DT, Leslie KO, Wilkerson MD, Qaqish BF, et al. Validation of interobserver agreement in lung cancer assessment: haematoxylin-eosin diagnostic reproducibility of non-small-cell lung cancer: the 2004 World Health Organisation classification and therapeutically relevant subsets. Arch Pathol Lab Med 2013; 37:32-40.
Whithaus K, Fukuoka J, Prihoda TJ et al. Evaluation of napsin-A, cytokeratin 5/6, p63 and thyroid transcription factor 1 in adenocarcinoma versus squamous cell carcinoma of the lung. Arch Pathol Lab Med.2012; 136:155-162.
National Cancer Registry Programme. Three Year Report of Population Based Cancer Registries: 2009-2011. Indian Council of Medical Research; 2013. Available from: http://www.ncrpindia.org, accessed on January 21, 2014.
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin2005; 55: 74-108.
Valaitis J, Warren S, Gamble D. Increasing incidence of adenocarcinoma of the lung. Cancer 1981; 47: 1042-6.
Malik PS, Sharma MC, Mohanti BK, Shukla NK, Deo S, Mohan A, et al. Clinico-pathological profile of lung cancer at AIIMS: A changing paradigm in India. Asian Pac J Cancer Prev2013; 14: 489-94.
Singh N, Aggarwal AN, Gupta D, Behera D, Jindal SK.et al. Unchanging clinico-epidemiological profile of lung cancer in north India over three decades. Cancer Epidemiol2010; 34: 101-4.
Jindal SK, Behera D. Clinical spectrum of primary lung cancer: Review of Chandigarh experience of 10 years. Lung India 1990; 8: 94-8.
Koul PA et al. “Lung cancer in the Kashmir valley “. Lung India 27.3(2010): 131-137.
Sheikh S, et al. “Histopathological pattern of Primary Malignant Lung Tumors Diagnosed in a Tertiary Care Hospital :10 -year studyâ€. Asian Pacific Journal of Cancer Prevention 111.5(2010): 1341-1346.
Mitesh R.R, Mithul B.M, Ramrao G, Nilkhanthe, Truti S, Dhaval H et al. A Detailed Study of Seventy Cases of Non-Small Cell Carcinoma of Lung, Immuohistochemical study and its Histo-Cytological Correlation. EC Pulmonology and Respiratory Medicine 2.3 (2016): 113-122.
Noronha V, Dikshit R, Raut N, Joshi A, Pramesh CS, George K, et al. Epidemiology of lung cancer in India: focus on the differences between non-smokers and smokers: a single-centre experience. Indian J Cancer 2012; 49: 74-81.
Mondal SK et al. “Computed tomogram guided fine-needle aspiration cytology of lung mass with histological correlation: A study in Eastern Indiaâ€. South Asian Journal of Cancer 2.1(2013): 14-18.
Himanshi D, Ajay Y, Jayanti M. Clinico-morphological and Immunohistochemical profile of Lung Carcinoma Specimens Received at a Tertiary care Centre: Journal Of Medical Science And Clinical Research Vol |[05]| Issue|[06]| Page 23103-23110|| June.
Grzegorz TG, Lei Z, Yuting W, Li C, Susan G, William CC et al. Utility of five commonly used immunohistochemical markers TTF1, Napsin-A, CK7, CK5/6 and P63 in primary and metastatic adenocarcinoma and squamous cell carcinoma of the lung: a retrospective study of 246 fine needle aspiration cases. Clinical and Translational Medicine (2015) 4:16.
Sterlacci W et al. Tissue-sparing application of the newly proposed IASLC/ATS/ERS classification of adenocarcinoma of the lung shows practical diagnostic and prognostic impact. Am J ClinPathol 2012 Jun; 137(6): 946-56.
Brunnstrom H et al. Immunohistochemistry in the differential diagnostics of primary lung cancer: an investigation within the Southern Swedish Lung Cancer Study. Am J ClinPathol 2013 Jul; 140(1): 37-46.
Zhao W et al. ΔNp63, CK5/6, TTF-1 and napsin-A, a reliable panel to subtype non-small cell lung cancer in biopsy specimens. Int J ClinExpPathol2014 Jun 15; 7(7): 4247-53.
Xu XY, Yang GY, Yang JH, Li J. Analysis of clinical characteristics and differential diagnosis of the lung biopsy specimens in 99 adenocarcinoma cases and 111 squamous cell carcinoma cases: utility of an immunohistochemical panel containing CK5/6, CK34βE12, p63, CK7 and TTF-1. Pathol Res Pract 2014 Oct; 210(10): 680-5.
Kargi A, Gurel D, Tuna B. The diagnostic value of TTF1, CK5/6 and p63 immunostaining in classification of lung carcinoma. Appl Immunohistochem Mol Morphol. 2007; 15: 415-20.
Sainz IM, Fukuoka J, Cagle PT, et al. Napsin-A: a new marker for lung adenocarcinoma is complementary and more sensitive than TTF-1 (thyroid transcription factor-1): evaluation of 967 cases by tissue microarray. Mod Pathol 2008; 21: 349A.
Bishop JA, Sharma R, Illei PB. Napsin-A and thyroid transcription factor-1expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol 2010 Jan; 41(1): 20-5.
Mukhopadhyay S, Katzenstein AL. Sub-classification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, Napsin-A, p63, and CK5/6. Am J SurgPathol 2011 Jan; 35(1): 15-25.
Banu Y, Deniz N, Pervin KE, Gursel C, Ali V. Expression of p63, TTF1and Mapsin in Non-Smallcell Lung Carcinoma and Their Effect on the Prognosis and Differential Diagnosis. Turk Pathol oji Derg 2015,31:163-174.
Lau SK, Luthringer DJ, Eisen RN. Thyroid transcription factor-1: a review. Appl Immunohistochem Mol Morphol 2002; 10: 97-102.
Hasanovic A, Rekhtman N, Sigel CS, Moreira AL. Advances in the fine needle aspiration cytology for the diagnosis of pulmonary carcinoma. Patholog Res Int. 2011; 8:972-92.37.
Clover J, Oates J, Edwards C. Anti-cytokeratin 5/6: a positive marker for epithelioid mesothelioma. Histopathology 1997; 31: 140–43.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 Alekhya M, Rukmangadha N, Lakshmi AY, Manickavasagam M
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).
